Personal responsibility is great, but it's not enough. We needed a collective effort to combat it, and vaccination was a very large part of that. Especially because asymptomatic or pre-symptomatic individuals could still spread it before they even test themselves.
The data clearly indicates that vaccination is safe and effective at reducing infection and subsequent death on a societal level. It also shows that vaccinated people are dramatically less likely to spread the infection due to lower viral load and infectious period duration.
Here's some more Data which is better than we can do speculating:
https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
RESULTS
In the vaccination analysis, the vaccinated and control groups each included a mean of 884,828 persons.
Vaccination was most strongly associated with an elevated risk of myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44;
risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6),
lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78;
risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2).
SARS-CoV-2 infection was associated with a substantially increased risk of myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8) and of additional serious adverse events, including pericarditis, arrhythmia, deep-vein thrombosis, pulmonary embolism, myocardial infarction, intracranial hemorrhage, and thrombocytopenia.
CONCLUSIONS
In this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.)